TRANSCODE THERAPEUTICS, INC.
  • Home
    • Mission
    • Clinical Trials
  • About
    • Metastatic Disease
    • Lead Candidate
    • Science
    • Pipeline >
      • Delivery Platform
      • Other Products
    • Leadership
  • Publications
  • Investors
  • Partnering

Pipeline

Our Pipeline

TransCode Therapeutics has created a platform of therapeutic candidates with the objective of improving cancer patient outcomes.

​Our lead therapeutic candidate, TTX-MC138, is focused on treating metastatic cancer, which has been shown to be responsible for the majority of all cancer deaths annually. 
More on TTX-MC138

Advancing a Pipeline of First-in-Class Therapeutic Candidates

Picture
Our other preclinical program includes a solid tumor program, TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1, or PD-L. TransCode also has two cancer agnostic programs, TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I, or RIG-I, targeting activation of innate immunity in the tumor microenvironment, and TTX-siMYC, a siRNA-based inhibitor of the c-myc oncogene.
Until now, targeting genetic markers that are the primary drivers of cancer onset, progression and recurrence have been locked behind the challenge of delivery – cytosolic delivery to engage these known targets.
other candidates
Picture

Downloadable Information Sheets

  • Decoding the Major Challenge of RNA Delivery
  • Advancing New RNA Therapies Through a Modular Approach
  • Lead Candidate TTXMC-138
  • TTX-siPDL1
  • 64Cu-TTX-MC138
  • TTX-RIGA
  • ​Diagnostic Approaches for Early Cancer Detection
TTX is an investigational platform encompassing therapeutic candidates (including TTX-MC138) and diagnostics which remain in development. Their safety and efficacy have not yet been evaluated by the FDA or any other regulatory agency.

Home

Mission
clinical trials
careers

​

About

​METASTATIC DISEASE
TTX-MC138
​SCIENCE
​PIPELINE
​DELIVERY PLATFORM
​OTHER PRODUCTS
​LEADERSHIP


Publications

​PUBLICATIONS

Partnering

partnering

Contact/Support

CONTACT
​TERMS OF USE
PRIVACY POLICY
FCOI Policy
​
© TRANSCODE THERAPEUTICS, INC. 2025.​ ALL RIGHTS RESERVED.
  • Home
    • Mission
    • Clinical Trials
  • About
    • Metastatic Disease
    • Lead Candidate
    • Science
    • Pipeline >
      • Delivery Platform
      • Other Products
    • Leadership
  • Publications
  • Investors
  • Partnering